In brief
Researchers have developed an unprecedented snake antivenom using antibodies from Tim Friede, a man who intentionally injected himself with snake venom for years. This innovative approach could lead to universal protection against snakebites, which claim up to 14,000 lives annually.
Article Text: A US man’s extraordinary journey of intentionally injecting himself with snake venom for nearly two decades has led scientists to develop what they describe as an "unparalleled" antivenom. The blood of Tim Friede contains antibodies that appear to shield against lethal amounts of venom from an array of snake species in animal testing. This advancement could signify a monumental breakthrough in the quest for a universal antivenom, addressing the critical public health issue of snakebites, which account for upwards of 14,000 fatalities annually, along with countless amputations or permanent disabilities.Mr. Friede has voluntarily endured over 200 snake bites and more than 700 venom injections from some of the world's most venomous snakes, such as various species of mambas, cobras, and kraits. Initially, his goal was to build immunity in order to safely handle snakes, which he documented extensively on YouTube. However, he admitted to experiencing life-threatening episodes, including a coma following two rapid cobra bites. He articulated a profound desire not only for survival but to create better treatments for snakebite victims globally, stating, "It just became a lifestyle... for the people who are 8,000 miles away from me who die from snakebite."Traditional antivenom production involves injecting animals, often horses, with snake venom, prompting their immune responses to create antibodies that scientists subsequently collect. However, this process requires a close match between the type of snake venom and the resulting antivenom, which can vary drastically even among snakes of the same species. To overcome this challenge, a team of researchers aimed to find broadly neutralizing antibodies that target common elements in entire classes of toxins, rather than the unique components of specific venoms.Dr. Jacob Glanville, CEO of the biotech firm Centivax, recognized that Friede’s unique blood could be a key to this search for broadly neutralizing antibodies and reached out to him. With ethical approval obtained, Friede agreed to donate blood for the study. The focus was primarily on elapids, a family of venomous snakes that rely on neurotoxins. Researchers identified 19 elapid species recognized by the World Health Organization as notably dangerous and turned to Friede’s blood for protective antibodies.Their findings, published in the journal Cell, reveal two broadly neutralizing antibodies capable of targeting two classes of neurotoxin. By incorporating a third drug, researchers created an antivenom cocktail that successfully tested on mice, allowing them to survive lethal doses from 13 of the 19 elapid snake species studied. Furthermore, animals showed partial protection from the remaining six, indicating "unparalleled" potential coverage, as noted by Dr. Glanville.The research team continues refining the antibodies, exploring the possibility of adding a fourth element to enhance protection against elapid venoms. While different snake families, like vipers, utilize hemotoxins that affect blood profiles, the progress made suggests an optimistic future in developing effective treatments for each toxin class. "In the next 10 to 15 years we'll have something effective against each one of those toxin classes," predicted Prof. Peter Kwong from Columbia University.Experts emphasize the ground-breaking nature of their findings but also stress the necessity for extensive further testing before clinical application. As Mr. Friede reflects on the breakthrough, he expresses a deep sense of fulfillment, recognizing the meaningful impact of his sacrifices on global health advancements: "I'm doing something good for humanity and that was very important to me. I'm proud of it. It's pretty cool."
